Sarcopenia Market to Register Incremental Growth During the Forecast Period 2032, Asserts DelveInsight | Key Companies – Eli Lily, Sanofi, Biophytis, Novartis, Amazentis, Immunoforge, and Regeneron

June 20 19:23 2022
Sarcopenia Market to Register Incremental Growth During the Forecast Period 2032, Asserts DelveInsight | Key Companies - Eli Lily, Sanofi, Biophytis, Novartis, Amazentis, Immunoforge, and Regeneron
Delveinsight Business Research LLP
DelveInsight’s “Sarcopenia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Sarcopenia Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Sarcopenia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Sarcopenia Market

Sarcopenia: An Overview

Sarcopenia is a condition that is characterized by loss of muscle mass, muscle strength, and functional muscle impairment with aging. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases.

Trials with various agents, including selective androgen receptor modulators and myostatin inhibitors, show promise as future treatment options. To date, methodological challenges and controversies regarding how best to define the condition, in addition to uncertainty about what outcome measures to consider, have delayed research into possible therapeutic options. To achieve that, increased awareness of sarcopenia is of great importance to begin reaching a consensus on diagnosis and to contribute to finding a cure for this condition.

Sarcopenia Market Key Facts

  • As per Society on Sarcopenia, Cachexia, and Wasting Disorders, the prevalence of sarcopenia ranges from 15% at 65 years to 50% at 80 years in humans, with normal aging associated with a 1–2% muscle loss beyond the age of 50 years.

  • As per Delveinsight estimates, the total prevalent population of sarcopenia in the 7MM was found to be 33,321,500+ in 2017.

  • The total prevalent cases of sarcopenia were the highest in the United States, followed by Italy and Germany. Spain accounted for the least number of prevalent cases among the 7MM.

  • Japan accounted for 2,890,000+ cases of sarcopenia in 2017, which accounted for approximately 8.67% of the total prevalent cases of sarcopenia in the 7MM.

Sarcopenia Market

The Sarcopenia market is anticipated to increase during the study period owing to the increasing prevalent population of sarcopenia patients in the 7MM. The expected launch of the emerging therapies will also create a positive shift in the market growth.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Sarcopenia market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Sarcopenia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Sarcopenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Sarcopenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sarcopenia market or expected to get launched during the study period. The analysis covers Sarcopenia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Sarcopenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Sarcopenia Therapeutics Analysis

Research is underway to identify therapeutic targets and develop a curative therapy for the treatment of sarcopenia. But, the current sarcopenia pipeline is poor with very few industry-funded trials.

Some of the key companies in the Sarcopenia Market include:

  • Eli Lily

  • Sanofi

  • Biophytis

  • Novartis

  • Amazentis

  • Immunoforge

  • Regeneron Pharmaceuticals

And many more. 

Sarcopenia Therapies covered in the report include:

  • Sarconeos

  • PF 1801

  • PB1023

  • Bimagrumab

  • AMAZ-02

  • Trevogrumab

  • LY2495655

And many others.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Sarcopenia Competitive Intelligence Analysis

4. Sarcopenia Market Overview at a Glance

5. Sarcopenia Disease Background and Overview

6. Sarcopenia Patient Journey

7. Sarcopenia Epidemiology and Patient Population

8. Sarcopenia Treatment Algorithm, Current Treatment, and Medical Practices

9. Sarcopenia Unmet Needs

10. Key Endpoints of Sarcopenia Treatment

11. Sarcopenia Marketed Products

12. Sarcopenia Emerging Therapies

13. Sarcopenia Seven Major Market Analysis

14. Attribute Analysis

15. Sarcopenia Market Outlook (7 major markets)

16. Sarcopenia Access and Reimbursement Overview

17. KOL Views on the Sarcopenia Market.

18. Sarcopenia Market Drivers

19. Sarcopenia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Campylobacter Infections Market

“Campylobacter Infections Market” research report delivers an in-depth understanding of the historical and forecasted epidemiology, Campylobacter Infections Market trends in 7MM as well as the key companies and the emerging therapies in the therapeutics domain.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States